Commentary

[摘要] This case illustrates the importance of understanding the limitations of immunoassay screening for drugs of abuse and the need for quantitative confirmation testing in patients using opioid medications for chronic noncancer pain therapy (1, 2). Specific guidelines written to help clinicians who prescribe opioids for pain management have recognized the urine drug screen as an aid in establishing compliance with the prescription regimen. The role of the urine drug test as an adjunct to pain therapy monitoring is that it primarily supplements …

[学科分类] 过敏症与临床免疫学